NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

NovoSeven is approved in the United States and the EU for several bleeding disorders, including hemophilia A or B with inhibitors, Factor VII deficiency, and Glanzmann’s thrombasthenia.

Pharmacokinetics Traditional pharmacokinetic studies recommend using a one-compartment model to calculate the pharmacokinetics of AHF, including in vivo recovery and elimination half-life (t 1/2 ...

Novo's historically more profitable biopharmaceutical arm (less than 10% of sales) includes hemophilia drug NovoSeven and endocrine therapy Norditropin.

Novo Nordisk Inc. has won an adverse jury instruction sanction against Washington state for its failure to preserve evidence in a False Claims Act case against the pharmaceutical company. Washington ...

NVO’s key marketed hemophilia therapies include NovoSeven and Esperoct, which generate incremental revenues for the company. NovoSeven is approved in the United States and the EU for several bleeding ...